Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis

被引：3

作者：

Hassing, Christina M. S. ^{[1
]}

Nielsen, Dorte Lisbet ^{[2
]}

Knoop, Ann Soegaard ^{[3
]}

Tvedskov, Tove Holst Filtenborg ^{[1
]}

Kroman, Niels ^{[1
]}

Laenkholm, Anne-Vibeke ^{[4
]}

Juhl, Carsten Bogh ^{[5
,6
,7
]}

Kuemler, Iben ^{[2
]}

机构：

[1] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Breast Surg, Gentofte Hosp Vej 1, DK-2900 Hellerup, Denmark

[2] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Oncol, Borgmester Ib Juuls Vej 7, DK-2730 Herlev, Denmark

[3] Copenhagen Univ Hosp, Dept Oncol, Sect 4262, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark

[4] Zealand Univ Hosp, Dept Surg Pathol, Sygehusvej 9,Postal Sygehusvej 10, DK-4000 Roskilde, Denmark

[5] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Physiotherapy & Occupat Therapy, Borgmester Ib Juuls Vej 1, DK-2730 Herlev, Denmark

[6] Univ Southern Denmark, Dept Sports Sci, Res Unit Musculoskeletal Funct & Physiotherapy, Campusvej 55, DK-5230 Odense, Denmark

[7] Univ Southern Denmark, Dept Clin Biomech, Res Unit Musculoskeletal Funct & Physiotherapy, Campusvej 55, DK-5230 Odense, Denmark

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 184卷

关键词：

Breast cancer; T1abN0; Human epidermal growth factor receptor 2; (HER2); Trastuzumab; Meta; -analysis; CHEMOTHERAPY; CANCER; WOMEN; CARCINOMAS; RECURRENCE; OUTCOMES; SUBTYPE; BENEFIT; IMPACT; RISK;

D O I：

10.1016/j.critrevonc.2023.103952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The benefit of adjuvant trastuzumab treatment in patients with HER2-positive breast tumors <= 10 mm without lymph node involvement (T1abN0) is insufficiently investigated. The aim of this systematic review and metaanalysis was to examine if adjuvant trastuzumab improves the prognosis in these patients. Databases were searched to identify interventional and observational studies evaluating the effect of trastuzumab on breast cancer specific survival (BCSS), disease free survival (DFS), distant recurrence free survival (DRFS), overall survival (OS) or recurrence free survival (RFS). Twelve studies examining the effect of trastuzumab and nine control studies without trastuzumab were identified (n = 6927). Median follow-up was 36-123 months. Significantly improved DFS (Hazard Ratio (HR) 0.14, p < 0.0001) and OS (HR 0.17, p = 0.011) were found for patients receiving trastuzumab and chemotherapy compared to no trastuzumab/chemotherapy based on four and two studies. The prognosis was good even for patients without trastuzumab treatment: 5-year DFS 88.3% and 5-year OS 95.9%.

引用

页数：11

共 48 条

[1] Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study [J].